Dynamics of beta-adrenoceptor blockade with cetamolol.
Open Access
- 1 April 1985
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 19 (4) , 411-416
- https://doi.org/10.1111/j.1365-2125.1985.tb02663.x
Abstract
Cetamolol is a new beta-adrenoceptor blocking agent shown in animals to have moderate beta 1-adrenoceptor selectivity and partial agonist activity. In healthy normal volunteers, beta 1-adrenoceptor blockade was measured as the reduction of exercise-induced tachycardia, systolic blood pressure, and double product at 2, 8, and 24 h after a single oral dose of 10, 25, and 50 mg cetamolol. beta 1-adrenoceptor blockade was significantly linearly related to log serum cetamolol level, was maximal at 2 h, and was still clinically significant at 24 h. A crossover study of single 0, 10, and 25 mg doses confirmed these findings.This publication has 7 references indexed in Scilit:
- Radioreceptor assay for serum levels of cetamolol, a new β-adrenoceptor antagonistClinical Biochemistry, 1984
- Central Hemodynamics of β-Adrenoceptor Blocking DrugsJournal of Cardiovascular Pharmacology, 1983
- Central hemodynamics of beta-adrenoceptor blocking drugs: beta 1 selectivity versus intrinsic sympathomimetic activity.1983
- Propranolol dosage, plasma concentration, and beta blockadeClinical Pharmacology & Therapeutics, 1982
- Adrenergic beta receptor blockade: Hemodynamic importance of intrinsic sympathomimetic activity at restClinical Pharmacology & Therapeutics, 1981
- Physical activity and the prevention of coronary heart disease.1971